WithdrawnPhase 4

Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis

China0Started 2016-01

Plain-language summary

The purpose of this study is to determine whether Urinary Kallikrein has an additional effect on enhancing collateral circulation in symptomatic intracranial atherosclerotic patients under clopidogrel and aspirin dual antiplatelet therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Acute ischemic stroke or TIA within 72 hours;
✓. Intracranial ICA, MCA M1 segment stenosis (\>70%)

Exclusion criteria

✕. \>70% Stenosis in an intracranial artery other than the culprit artery.
✕. \>50% Stenosis of an extracranial carotid or vertebral artery on the ipsilateral side.
✕. Perforator strokes based on MRI.
✕. Non-atherosclerotic lesion, for example, moyamoya disease, vascular inflammatory disease due to infection, autoimmunity diseases, developmental or genetic abnormalities, for example, fibromuscular dysplasia, sickle-cell anaemia, suspected vasospasm.
✕. Potential cardiac embolism as cause.
✕. Intracranial haemorrhage within 6 weeks.
✕. Concomitant intracranial tumour, aneurysm or arteriovenous malformation.
✕. Known contraindications for heparin, aspirin, clopidogrel or contrast.

What they're measuring

the percentage of patients with modified Rankin Score (mRS) equivalent to or less than 2

Timeframe: 3 months

Trial details

NCT IDNCT04325932

SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-05

View on ClinicalTrials.gov More Intracranial Arteriosclerosis trials